A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic전염병 통제를 위한 기초로서 SARS-CoV-2 및 COVID-19의 바이러스 특성, 전파, 병태생리학, 면역 반응 및 관리에 대한 종합적인 검토Review Published on 2021-02-262022-09-11 Journal: Frontiers in Immunology [Category] MERS, 변종, 치료제, [키워드] Antarctica anti-inflammatory drug approved Asymptomatic Basis causative pathogen children China clinical presentation Clinical presentations Comprehensive controlling coronavirus country COVID vaccines COVID-19 curative Dexamethasone drug drugs effective facilitate failure Genome globe Healthcare system Healthcare systems Hydroxychloroquine immune response infected case knowledge Mechanics mode Mortality negatively affected not reduce pathophysiology Patient positive Prevent promote provide Reinfection Remdesivir response review risk RNA polymerase inhibitor SARS-CoV-2 significantly Spread spread to susceptibility the disease Transmission Trial Vaccine development variants Variation variations virus virus transmission [DOI] 10.3389/fimmu.2021.631139 PMC 바로가기 [Article Type] Review
Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 TherapeuticsCOVID-19 치료제 개발을 위한 바이러스 감염 메커니즘 및 환자 증상 이해Review Published on 2021-02-092022-09-10 Journal: International Journal of Molecular Sciences [Category] MERS, 진단, 치료제, [키워드] ACE2 acute respiratory distress acute respiratory distress syndrome anti-inflammatory drug Anti-inflammatory drugs Antiviral ARDS basic camostat mesilate caused cells changes in clinician coronavirus disease Coronavirus disease 2019 cough Course COVID-19 COVID-19 patient COVID-19 patients COVID-19 symptoms COVID-19 therapeutics death develop development drug fatigue Fever immunomodulation infect information inhibiting knowledge mechanism Mild mortality rate Organ failure Pathogenesis pathogenesis of COVID-19 Patient replicate Replication researcher respiratory distress SARS-CoV-2 SARS-CoV-2 virus severe COVID-19 severe pneumonia Symptom Symptomatic treatment syndrome systemic inflammation the SARS-CoV-2 virus Therapeutics tissue damage TMPRSS2 treat treatment strategy understanding Viral viral titers virus virus clearance virus infection worldwide pandemic [DOI] 10.3390/ijms22041737 PMC 바로가기 [Article Type] Review
Disease burden in a large cohort of asylum seekers and refugees in GermanyArticles Published on 2021-01-302022-10-31 Journal: Journal of Global Health [Category] COVID-19, [키워드] African age Analysis anti-inflammatory drug Asylum average Care classification clinics Cohort complaint conducted cross-sectional demographic data diagnose diagnoses disease female Germany Health care system ICD initial large cohort medical record medication middle Most patient Musculoskeletal Patient Prevalence proportion refugee respiratory infections Respiratory system Result the patient were recorded [DOI] 10.7189/jogh.11.04002 PMC 바로가기 [Article Type] Articles
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus코로나바이러스의 스파이크 당단백질에 대한 항말라리아제, 항바이러스제, 항염증제 및 HIV 프로테아제 억제제의 분자 스크리닝Article Published on 2021-01-012022-09-11 Journal: Journal of molecular graphics & modelling [Category] SARS, 신약개발, 치료제, [키워드] ACE2 receptor ACE2 receptor binding Amino acid Analysis Anti-inflammatory anti-inflammatory drug Anti-inflammatory drugs antibiotic antibiotic drug antibiotic drugs antimalarial antimalarial drug Antimalarial drugs Antiviral antiviral drug target antiviral drugs applied Artemisinin Baricitinib Chloroquine Clinical studies clinical study Cobicistat coronavirus CoV COVID-19 darunavir docking docking score drug Efficacy and safety erythromycin glycoprotein H-bonds help high mortality rate HIV protease inhibitor homology modeling host cell host cells Human Hydroxychloroquine immunogenic inhibitor inhibitors interactions lead Lopinavir methodology molecular docking outbreak pharmacological preclinical studies preclinical study Protein Ritonavir ruxolitinib screened spike spike glycoprotein Spike protein Spiramycin thalidomide the patient therapeutic Treatment Treatment strategies Viral viral disease viral entry Virtual screening [DOI] 10.1016/j.jmgm.2020.107769 PMC 바로가기 [Article Type] Article
Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative ReviewReview Published on 2020-12-122022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] “cytokine storm” acute respiratory syndrome Anti-inflammatory anti-inflammatory drug Anti-inflammatory drugs anti-viral drug approach benefit Care challenge clinical care Clinical practice clinical trial clinician complementary condition Coronavirus-2 COVID-19 COVID-19 disease COVID-19 patient Cytokine storm develop disease severity drug early stage effective effective therapy effort Evidence expected global pandemic Host Hypothesis immune defense immunomodulation immunomodulatory activities Infection Inflammation Inflammatory introduced management morbidity and mortality narrative novel coronavirus disease opportunity patients pro-inflammatory cytokine Replication Research response review risk Safe SARS-CoV-2 SARS-CoV-2 entry severe cases Spread targeting the disease therapy Vaccines virus while worsening [DOI] 10.3390/jcm9124021 PMC 바로가기 [Article Type] Review
Alpha-1 Antitrypsin for COVID-19 Treatment: Dual Role in Antiviral Infection and Anti-InflammationPerspective Published on 2020-12-112022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] Activation acute lung injury acute respiratory distress acute respiratory distress syndrome (ARDS) acute respiratory syndrome alpha-1 antitrypsin (A1AT) Anti-inflammation Anti-inflammatory anti-inflammatory drug Anti-inflammatory therapy antitrypsin Antiviral antiviral therapy approaches approved Blood cell death circulating clinical trial Coagulation coronavirus coronavirus disease 2019 (COVID- 19) COVID-19 COVID-19 disease COVID-19 patient deficiency demonstrated determine drug effective emphysema entry of SARS-CoV-2 glycoprotein host cells Human Infection Inflammation inhibit inhibiting involved moderate Neutrophil elastase Patient Prevent protease Protease inhibitor reducing role SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) severe lung injury syndrome therapy TMPRSS2 transmembrane serine protease treat Treatment unique [DOI] 10.3389/fphar.2020.615398 PMC 바로가기 [Article Type] Perspective
Additional baricitinib loading dose improves clinical outcome in COVID-19Research Article Published on 2020-12-052022-10-28 Journal: Open Medicine [Category] COVID-19, [키워드] accounted anti-inflammatory drug Baricitinib Blood oxygen saturation case-control study Clinical outcome control group coronavirus disease COVID-19 COVID-19 pneumonia daily dose effective enrolled high mortality rate IMPROVE inhibitor intensive care Jak Janus kinase Loading dose maintenance dose management mechanical ventilation support median moderate-to-severe COVID-19 pneumonia normal breathing function Patient patients with COVID-19 Pneumonia severe COVID-19 treated [DOI] 10.1515/med-2021-0010 PMC 바로가기 [Article Type] Research Article
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2Article Published on 2020-12-042022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] activity alleviate Anti-inflammatory anti-inflammatory drug antimicrobial drugs Antiviral antiviral activity approach Azithromycin binding Combination coronavirus 2 COVID-19 COVID-19 pandemic COVID-19 patients disease drug Drug discovery Drug repurposing drugs Evidence food Hydrogen bond impair in vitro Interaction Ligand MERS-CoV Middle East niclosamide nitazoxanide PDB peptide Piroxicam potent protease provided reduce Replication reported respiratory respiratory symptoms SARS-CoV-2 SARS-CoV-2 replication spike glycoprotein tested Therapeutic benefit Virtual screening [DOI] 10.3390/ph13120443 PMC 바로가기 [Article Type] Article
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort studyResearch article Published on 2020-12-012022-10-05 Journal: Saudi Pharmaceutical Journal : SPJ [Category] 치료법, [키워드] Abdul adjusted Admission age age and gender anti-inflammatory drug Antiviral Aziz cohort study conducted coronavirus disease COVID-19 COVID-19 patient discharge Effectiveness Efficacy eligible evaluate generalized linear regression HCQ hospital Hospital stay Hospitalization Hospitalized Hydroxychloroquine ICU ICU admission inclusion criteria investigated knowledge laboratory-confirmed Length less Logistic regression Lopinavir/ritonavir mechanical ventilation Mild Ministry of Health moderate no significant difference observational study outcome outcomes Patient patients with COVID-19 previous study Prince protocols RCT regimen regression analysis Result retrospective cohort study Saudi Arabia standard care standard treatment treated Treatment treatment for COVID-19 two group variables [DOI] 10.1016/j.jsps.2020.09.019 [Article Type] Research article
Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?Pharmacology Published on 2020-10-072022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] ACE2 airway angiotensin-converting enzyme 2 anti-inflammatory drug antioxidant Antiviral authority bacterial superinfection cells COVID-19 COVID-19 pandemic COVID-19 patient depleting disease symptoms drug early phase effort Fever glutathione GSH Hospitalized Host Hypothesis increased risk Inflammation management medication Non-steroidal anti-inflammatory drugs NSAID NSAIDS oxidative damage Pain Paracetamol question raise raised receptor Research Risk factors SARS-CoV2 severely ill patients Symptoms the disease treat Treatment viral infection viral infections [DOI] 10.3389/fphar.2020.579944 PMC 바로가기 [Article Type] Pharmacology